Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To decrease length of high-flow nasal cannula (HFNC), PICU, and hospital length of stay (LOS).
Design: Quality improvement project.
Setting: A quaternary academic PICU.
Patients: Patients with bronchiolitis less than 24 months old.
Interventions: After initial implementation of a respiratory therapist (RT)-driven HFNC protocol (Plan-Do-Study-Act [PDSA] 1) in October 2017, additional interventions included adjusting HFNC wean rate (PDSA 2) in July 2020, a HFNC holiday (PDSA 3), and standardized discharge criteria (PDSA 4) in October 2021.
Measurements And Main Results: Duration of HFNC was used as the primary outcome measure. PICU LOS and hospital LOS were used as secondary outcome measures. Noninvasive ventilation use, invasive mechanical ventilation use, and 7-day PICU and hospital readmission rates were used as balancing measures. A total of 1,310 patients were included in this study. Patients in PDSA 2, PDSA 3 and 4 groups were older compared with pre-intervention and PDSA 1 (median of 9 and 10 mo compared with 8 mo; p = 0.01). HFNC duration decreased from 2.5 to 1.8 days after PDSA 1, then to 1.3 days after PDSA 2. PICU LOS decreased from 2.6 to 2.1 days after PDSA 1, 1.8 days after PDSA 2, and 1.5 days after PDSA 3 and 4. Hospital LOS decreased from 5.7 to 4.5 days after PDSA 1, 3.1 days after PDSA 2, and 2.7 days after PDSA 3 and 4. The use of noninvasive ventilation and invasive mechanical ventilation decreased throughout the study from 23.2% in the pre-intervention group, to 6.9% at the end of the project. The 7-day PICU and hospital readmission rates did not increase after implementation. The percentage of patients discharged from the PICU increased from 6.2% to 21.5%.
Conclusions: Modifications to an existing RT-driven HFNC protocol and standardization of discharge criteria led to an improvement in outcomes for patients admitted to the PICU with bronchiolitis without an increase in adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PCC.0000000000003183 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevention of unplanned extubation in neonates with silk tie securement.
Pediatr Res
June 2025
Neonatology, Cleveland Clinic Children's Hospital, Cleveland, OH, USA.
Background: Unplanned extubation (UE) is the fourth most common adverse event in neonatal intensive care units (NICUs) and remains a significant global challenge. Standardizing endotracheal tube (ETT) maintenance could reduce UE rates to 0.5-1.
View Article and Find Full Text PDFPatient-Centered Genomic Diagnostic Testing for AML: A Quality Improvement Project.
JCO Oncol Pract
June 2025
Division of Hematology, Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, Canada.
Purpose: The classification of AML and therapeutic options are now largely driven by genetically defined subtypes. Personalization of treatment relies on timely completion and reporting of cytogenetic and molecular tests, creating challenges in clinical practice. We initiated a quality improvement study with the aim to optimize the process for ordering of genomic diagnostic tests and to reduce test turnaround times (TATs).
View Article and Find Full Text PDFReduction in the Concomitant Ordering of Erythrocyte Sedimentation Rate and C-Reactive Protein Within a Large Academic Medical Center.
J Gen Intern Med
May 2025
Rheumatic Diseases Division, University of Texas Southwestern Medical Center, 2001 Inwood Rd, Dallas, TX, 75390-8887, USA.
Background: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are two laboratory tests often ordered simultaneously to assess for inflammation. Studies show that CRP is superior to ESR, and co-ordering ESR and CRP increases expenditures and phlebotomy without demonstrable patient benefit.
Objective: Our quality improvement project aimed to reduce ESR/CRP co-ordering and total ESR orders in a safety-net health setting (health system 1) and a university setting (health system 2) within an academic medical center.
Improved oral anticancer medication (OAM) adherence/toxicity assessment documentation: A quality improvement initiative.
J Oncol Pharm Pract
May 2025
Division of Hematology/Oncology, University of Virginia, Charlottesville, USA.
IntroductionAdherence and toxicity symptoms ideally are monitored within 7-14 days after initiating oral anticancer medication (OAM). After implementing a formal OAM program at our institution, we found our adherence and toxicity monitoring was suboptimal and sought to improve our processes to reduce patient risk, using a formal quality improvement methodology.Patient and methodsAdult patients with a solid tumor or hematologic malignancy newly prescribed on OAM were included.
View Article and Find Full Text PDFQuality improvement project to reduce beta-D-glucan turnaround times in an NHS pathology network.
BMJ Open Qual
May 2025
Alliance Manchester Business School, The University of Manchester, Manchester, UK.
Beta-D-glucan (BDG) is a cell wall component of many fungi, detecting this in patients' serum permits early diagnosis of invasive fungal infections, particularly in patients with haematological malignancy. In critically ill patients in an intensive-care unit, where the prevalence of invasive fungal infection is lower, the high negative predictive value of BDG facilitates withholding or discontinuation of empirical antifungal therapy, contributing to antifungal stewardship. However, for the results of BDG testing to impact patient management, they need to be available within a clinically useful timeframe.
View Article and Find Full Text PDF